In light of the FDA's action against 23andMe and the failure of genotype-guided dosing for warfarin, I think we are more than five years away. Though genotyping has now reached speed and pricing levels to make it practical, we still need to figure out how to practice genomic medicine.
At the intersection of medicine and technology